Gabapentin works by reducing calcium flow into nerve cells, which quiets the release of chemical signals involved in pain and seizures. Despite its name resembling GABA (a calming brain chemical), gabapentin does not actually bind to GABA receptors or directly affect GABA levels. Its real target is a specific protein on calcium channels in the nervous system, and understanding that mechanism explains both why the drug helps and why it behaves unusually in the body.
The Core Mechanism: Calcium Channels
Nerve cells communicate by releasing chemical messengers called neurotransmitters. Before a nerve cell can release these messengers, calcium ions need to flow into the cell through tiny gated openings called voltage-gated calcium channels. Gabapentin attaches to a particular piece of these channels, a protein subunit known as alpha-2-delta-1, and binds to it tightly.
This binding doesn’t block the calcium channel directly the way a plug stops a drain. Instead, gabapentin interferes with how the cell recycles and restocks these channels at its surface. Normally, used channels get pulled inside the cell, refurbished, and sent back to the membrane. Gabapentin disrupts that recycling process, so over time fewer calcium channels are available at the nerve ending. With fewer channels open, less calcium enters the cell, and the nerve releases smaller amounts of excitatory neurotransmitters, particularly glutamate and substance P, a molecule heavily involved in pain signaling.
This is why gabapentin doesn’t work instantly. The drug needs time to reduce the number of active channels, which is also why doctors typically start at a low dose and increase it over several days.
Why the Name Is Misleading
Gabapentin was originally designed to mimic GABA, the brain’s primary calming neurotransmitter. Structurally, it looks like GABA, and its name reflects that intention. But research has shown it does not bind to GABA receptors, does not get converted into GABA, and does not inhibit the enzymes that break GABA down. Its calming effects come entirely from reducing excitatory signaling through the calcium channel mechanism described above. The resemblance to GABA is essentially a historical accident of drug design.
How It Reduces Pain
In nerve pain conditions, damaged or irritated nerves fire excessively, flooding the spinal cord and brain with glutamate and substance P. These chemicals amplify pain signals, sometimes to the point where even light touch feels painful. By limiting calcium influx at nerve terminals, gabapentin dials down this overactive signaling. It also appears to counteract some of the inflammatory pathways triggered by substance P, based on lab studies showing it can block a key inflammation-promoting protein (NF-kB) that substance P activates.
The FDA has approved gabapentin for two specific conditions: postherpetic neuralgia (the lingering nerve pain that can follow a shingles outbreak) and partial onset seizures in epilepsy, where it’s used alongside other seizure medications. Doctors also prescribe it off-label for other types of nerve pain, and a randomized clinical trial published in JAMA Internal Medicine found it significantly increased total abstinence rates in people being treated for alcohol use disorder, particularly those with more severe withdrawal symptoms. In that study, 41% of participants with high withdrawal symptoms achieved total abstinence on gabapentin compared to just 1% on placebo.
Absorption Gets Less Efficient at Higher Doses
Gabapentin has an unusual quirk that sets it apart from most medications. Your intestines absorb it using a specific amino acid transporter, the same system your gut uses to absorb the amino acid leucine from food. These transporters have a limited capacity. At lower doses, they can shuttle most of the drug into your bloodstream efficiently. But as the dose increases, the transporters become saturated, like a ferry that can only carry so many passengers per trip. This means doubling your dose does not double the amount of drug that actually reaches your blood.
This saturation effect is one reason gabapentin is typically taken three times a day rather than in one large dose. Spreading it out gives the transporters time to work through each dose more completely.
Elimination and Kidney Function
Once absorbed, gabapentin is not broken down by the liver at all. It circulates through the body unchanged and is cleared entirely by the kidneys. In people with normal kidney function, the drug’s half-life (the time it takes for blood levels to drop by half) is relatively short, which is another reason for multiple daily doses. In people with reduced kidney function, the drug stays in the body longer, blood levels climb higher, and side effects become more likely. Dosing adjustments are based on how well the kidneys are filtering, measured by creatinine clearance.
Common Side Effects
The most frequently reported side effects in clinical trials reflect gabapentin’s core action of dampening nerve signaling. Sleepiness affects roughly 21% of people taking it, dizziness about 17%, and problems with coordination (ataxia) around 13%. Peripheral edema, or swelling in the hands and feet, is also common. These effects tend to be most noticeable when starting the medication or increasing the dose, which is why the typical starting protocol for postherpetic neuralgia ramps up gradually: 300 mg on day one, 600 mg on day two, and 900 mg on day three.
Interactions With Antacids
If you take magnesium-based antacids alongside gabapentin, your body absorbs significantly less of the drug. One study found that magnesium oxide reduced gabapentin’s overall absorption by about 32%, with peak blood levels dropping by 33%. This reduction appears to stem from the antacid physically interfering with intestinal absorption rather than from changes in stomach acid levels, since acid-suppressing medications like omeprazole did not cause the same problem. If you use antacids, spacing them at least two hours from your gabapentin dose helps avoid this interaction.
Controlled Substance Status
Gabapentin is not a federally scheduled controlled substance in the United States. In 2023, the FDA denied a petition to begin scheduling proceedings at the federal level. However, as of December 2024, seven states classify it as a Schedule V controlled substance (the least restrictive category) and require pharmacies to report prescriptions to their state’s prescription drug monitoring program. Another 17 states require the monitoring program reporting without formally scheduling the drug. The American Medical Association has actively opposed scheduling gabapentin but supports ongoing research into risks when it’s used alongside opioids.